Photovoltaic-enhanced water splitting properties of low-temperature-synthesized BiVO4 photoanode films.

The fabrication of photoelectrodes on indium tin oxide (ITO) glass at low temperatures poses a significant challenge due to the inherent instability of ITO at reduced temperatures, while the inexpensive production of high-functionality photoanode technology is a critical determinant facilitating large-scale photovoltaic conversion in water splitting. In this work, highly efficient BiVO4 (BVO) photoanodes with different thicknesses were grown on ITO glass at a low temperature by the sol-gel spin coating method. Pure BVO photoanode, enriched with nanostructures, exhibits a current density of 2.25 mA cm-2 (@1.23 V vs. RHE) under AM-1.5G illumination. The photovoltaic effect induces a continual oxygen evolution reaction at zero bias voltage on the photoanode, resulting in a photocurrent density of 0.04 mA cm-2 at zero bias. This study not only evaluates the feasibility of the large-scale fabrication of a photoanode from economic considerations but also presents potential for water splitting properties of the BVO photoanode.

Case report: Acrodermatitis enteropathica result from a novel SLC39A4 gene mutation.

The clinical data and gene sequencing results in a child with acrodermatitis enteropathica were retrospectively reported, and the related literature was reviewed. A girl aged 9 years and 4 months presented with a repeated skin rash, mainly distributed in the perioral, anogenital, and acral areas, accompanied with alopecia, and a low blood zinc level was found many times. A significant improvement was seen after continuous zinc supplementation. The genetic sequencing test demonstrated that the patient had compound heterozygous for two SLC39A4 mutations: c.1466dupT (p.S490Efs*155) and c.295G > A (p.A99T), and her parents were heterozygous carriers of these two mutations. An improvement was achieved after continuous zinc supplementation. This case report might guide further research on this aspect.

Genotypic and Phenotypic Analyses of Two "Isogenic" Strains of the Human Fungal Pathogen Cryptococcus neoformans var. neoformans.

The Cryptococcus neoformans species complex is a model organism for fungal studies. Many studies have used two strains, JEC20 and JEC21, and their derivatives. These two strains were obtained through 10 rounds of backcrosses and have been assumed near identical except at the mating-type locus. Here we obtained and compared the JEC20 genome sequence with the published "JEC21" genome. Our comparison revealed 5322 single nucleotide polymorphisms (SNPs) with the majority (N = 3816, 71.7%) located in three genomic regions, including the previously noted mating-type region. The remaining 1506 SNPs (28.3%) were distributed throughout all 14 chromosomes, predominantly at chromosomal ends. To study the potential effects of these three SNP-rich regions on phenotypes, 24 progenies from the JEC20 × JEC21 cross representing eight recombinant genotypes were analyzed for their mating ability, melanin production, capsule formation, and growths at 30 °C and 40 °C. Significant phenotypic variations were found among the progeny. However, the observed phenotypic variations could not be explained by the three SNP-rich regions. Further genome sequencing of our JEC21 and the 24 progenies revealed only six segregating SNPs outside of the three SNP-rich regions between JEC20 and JEC21, a result indicating that the 1500 SNPs identified in the published "JEC21" genome might be caused by sequencing errors and/or strain mixing. However, the six SNPs and the three SNP-rich regions could not explain the observed phenotypic variations. Our analyses suggest that spontaneous mutations accumulated under laboratory conditions could have significant effects on phenotypes and on our interpretations of experimental results.

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy.

Immunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpoint inhibitor treatment, including tumor-specific profiles and tumor microenvironment evaluation and other factors.